YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
The available CDE acceptance records list 419 drug applications between 11 November 2026 and 17 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 73, covering 50 drug names.
2026/11/11 – 2026/11/17
- New acceptances this week
- 419
- Drugs with new generic filings (by drug name, de-duplicated)
- 50
- Accepted this week, now under review
- 419
DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.
Names with a public page are linked.
New acceptances this week
By application type and drug type
419filings, 73 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 215 |
| New drug | 89 |
| Generic | 73 |
| Import | 32 |
| Unspecified | 5 |
| Import re-registration | 5 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 243 |
| TCM | 98 |
| Therapeutic biologic | 67 |
| Biologic | 6 |
| Prophylactic biologic | 5 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
50 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | Polyvinyl Alcohol Eye Drops | 3 | 2 | 26 |
| 2 | Mirogabalin Besilate Tablets | 3 | 2 | 64 |
| 3 | Fosfomycin Sodium For Injection | 3 | 1 | 16 |
| 4 | 西诺氨酯片 · No verified English name | 3 | 1 | 23 |
| 5 | Tafluprost Eye Drops | 2 | 2 | 3 |
| 6 | Rosuvastatin Calcium and Ezetimibe Tablets (I) | 2 | 2 | 7 |
| 7 | Trazodone Hydrochloride Sustained-release Tablets | 2 | 2 | 22 |
| 8 | Buprenorphine Hydrochloride and Naloxone Hydrochloride Sublingual Tablets | 2 | 1 | 2 |
| 9 | Ethyl Iosapentate Capsules | 2 | 1 | 25 |
| 10 | Dotinurad Tablets | 2 | 1 | 56 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
250 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 | 0 |
| 2 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | 7 | 3 | 0 |
| 3 | Eli Lilly and Company | 6 | 3 | 0 |
| 4 | CISEN PHARMACEUTICAL CO., LTD. | 6 | 3 | 3 |
| 5 | Novo Nordisk A/S | 6 | 1 | 0 |
| 6 | Suzhou Ya Sheng Pharma Co., Ltd. romanized | 6 | 1 | 0 |
| 7 | Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized | 5 | 5 | 0 |
| 8 | Anhui Sheng Jing Cheng Hui Yao Pharma Co., Ltd. romanized | 5 | 3 | 0 |
| 9 | Boehringer Ingelheim International GmbH | 5 | 2 | 0 |
| 10 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 4 | 2 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Based on changes in CDE's under-review list
- Entered review this week
- 419
- Left the under-review list this week
- 565
Of these, NMPA published approval-document delivery for 232 (including 222 supplemental applications, not counted as new marketing approvals) and notification delivery for 16; the outcome of the other 317 is to be checked.
Most filings leaving review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized | 13 | 3 |
| 2 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | 9 | 3 |
| 3 | AbbVie Inc. | 8 | 1 |
| 4 | Rui Li Shi Wan Ting Min Xin Pharmaceutical Co., Ltd. romanized | 7 | 1 |
| 5 | Luo Yang Yi Long Pharma Co., Ltd. romanized | 6 | 6 |
| 6 | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 6 | 5 |
| 7 | Novartis Pharma AG | 6 | 4 |
| 8 | Shanghai Han Sen Biopharmaceuticals Technology Co., Ltd. romanized | 5 | 5 |
| 9 | Li Shi Zhen Pharmaceuticals Group Co., Ltd. romanized | 5 | 4 |
| 10 | Shanghai Kai Mao Biopharmaceuticals Co., Ltd. romanized | 5 | 1 |
Most filings entering review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Novo Nordisk A/S | 11 | 2 |
| 2 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 8 | 4 |
| 3 | F. Hoffmann-La Roche Ltd | 8 | 2 |
| 4 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | 7 | 3 |
| 5 | Henan Pu Rui Pharma Co., Ltd. romanized | 6 | 4 |
| 6 | CISEN PHARMACEUTICAL CO., LTD. | 6 | 3 |
| 7 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | 6 | 1 |
| 8 | Suzhou Ya Sheng Pharma Co., Ltd. romanized | 6 | 1 |
| 9 | Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized | 5 | 5 |
| 10 | Yichang Humanwell Pharmaceutical Co., Ltd. | 5 | 3 |
DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
137 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600517 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600516 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Import · Class 1 | LUM-201胶囊 · No verified English nameJXHL2600515 | Lumos Pharma LLC; ICON Clinical Research (Beijing No. 2) Co. Ltd. |
| 2026/11/17Generic · Class 3 | 恩那度司他片 · No verified English nameCYHS2602837 | Shandong Loncom Pharmaceutical Co., Ltd. |
| 2026/11/17Generic · Class 3 | 恩那度司他片 · No verified English nameCYHS2602836 | Shandong Loncom Pharmaceutical Co., Ltd. |
| 2026/11/17Generic · Class 3 | 血管紧张素Ⅱ注射液 · No verified English nameCYHS2602828 | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD |
| 2026/11/17New drug · Class 1 | XKH001注射液 · No verified English nameCXSL2601280 | Xin Kang He Biopharmaceuticals (Beijing) Co., Ltd. romanized; Beijing Xin Kang He Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | DC01注射液 · No verified English nameCXSL2601279 | Chengdu Bo An Zhi Yan Xi Bao Bio Technology Co., Ltd. romanized; Sichuan Zhong Ke Ding Yao Xi Bao Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | PTT-936口服冻干粉 · No verified English nameCXHL2601446 | Beijing Yan Ming Bio Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 2.1; 2.2; 2.4 | HW-N2001注射液 · No verified English nameCXHL2601445 | HARWAY PHARMA CO.,LTD. |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601444 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601443 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/17New drug · Class 1 | ZL-69胶囊 · No verified English nameCXHL2601442 | Chengdu Ze Ling Biopharmaceuticals Technology Co., Ltd. romanized |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600322 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600321 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600320 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600319 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600318 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | Zenagamtide片 · No verified English nameJXSL2600317 | Novo Nordisk A/S; Novo Nordisk (China) Pharmaceuticals Co. Ltd |
| 2026/11/16Import · Class 1 | PF-08634404 · No verified English nameJXSL2600316 | Pfizer Inc.; Pfizer (Beijing) Research and Development Co. Ltd. |
| 2026/11/16Import · Class 1 | BI 3034701注射液 · No verified English nameJXHL2600514 | Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd |
| 2026/11/16Import · Class 1 | BI 3034701注射液 · No verified English nameJXHL2600513 | Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd |
| 2026/11/16Import · Class 1 | BI 3034701注射液 · No verified English nameJXHL2600512 | Boehringer Ingelheim International GmbH; Boehringer Ingelheim (China) Investment Co. Ltd |
| Import · Class 1 | BI 3034701注射液 · No verified English name | — |
| 2026/11/16Generic · Class 3 | Brexpiprazole Orally Disintegrating TabletsCYHS2602824 | Yunpeng Pharmaceutical Group Co., Ltd. |
| 2026/11/16Generic · Class 3 | Brexpiprazole Orally Disintegrating TabletsCYHS2602823 | Yunpeng Pharmaceutical Group Co., Ltd. |
| 2026/11/16Generic · Class 3 | 亚硒酸钠注射液 · No verified English nameCYHS2602819 | TC Pharmaceuticals (Jiangsu) Co., Ltd |
| 2026/11/16Generic · Class 3 | Benzbromarone TabletsCYHS2602817 | Shouguang Fukang Pharmaceutical Co., Ltd. |
| 2026/11/16Generic · Class 3 | Dequalinium Chloride Buccal TabletsCYHS2602815 | Huayi Pharmaceuticals (Anhui) Co., Ltd. |
| 2026/11/16New drug · Class 1 | 韦立斯托赛注射液 · No verified English nameCXSS2600189 | Shanghai Ai Sa Er Biopharmaceuticals Co., Ltd. romanized |
107 more not listed (at most 30 rows).
For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.